1-6 of 6
Smitha Sivaraman
Close
Sort by
Journal Articles

Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel or Other Donor Sources in Patients with Hematologic Malignancies: Comparison of Clinical Trial Results to Center for International Blood and Marrow Transplant Research Database Controls

Smitha Sivaraman, Gautam Sajeev, Yan Song, Chunyi Xu, Chujun He, James E. Signorovitch, Heayoung Shin, Rocio Manghani, Xiao-Ying Tang, Mei-Je Zhang, Linda J Burns, Ronit Simantov
Journal: Blood
Blood (2022) 140 (Supplement 1): 660–661.
https://doi.org/10.1182/blood-2022-162439
Published: 2022
Journal Articles

Hospitalization and Healthcare Resource Use of Omidubicel Vs Cord Blood Transplantation for Hematological Malignancies in a Global Randomized Phase III Clinical Trial

Navneet S. Majhail, Beckley Miller, Rebecca Dean, Rocio Manghani, Smitha Sivaraman, Einat Galamidi-Cohen, Richard T. Maziarz
Journal: Blood
Blood (2021) 138 (Supplement 1): 4036.
https://doi.org/10.1182/blood-2021-147480
Published: 2021
Journal Articles

Disease and Clinical Characteristics of Patients with Essential Thrombocythemia Enrolled in the MOST Study

Abdulraheem Yacoub, MD, Roger M. Lyons, MD, Srdan Verstovsek, MD PhD, Ryan Shao, MD, David Tin Chu, MD, Apurv Agrawal, MD, Smitha Sivaraman, PhD, Philomena Colucci, DO, MS, Peter Yao, John Mascarenhas, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4306.
https://doi.org/10.1182/blood-2018-99-112183
Published: 2018
Journal Articles

Real-World Patterns of First-Line Hydroxyurea Treatment Among Patients with Essential Thrombocythemia in US Community Oncology Practices

Jingbo Yu, PhD, Philomena Colucci, DO, MS, Dilan Chamikara Paranagama, PhD, Smitha Sivaraman, PhD, Pavel Atanasov, Becky Hanna, Jackson Tang, Shreekant V. Parasuraman, BPharm, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4203.
https://doi.org/10.1182/blood.V130.Suppl_1.4203.4203
Published: 2017
Journal Articles

Characteristics of 809 Patients with Essential Thrombocythemia in Real-World Clinical Practice: A Chart Review Study in the United States

Jingbo Yu, PhD, Philomena Colucci, DO, MS, Dilan Chamikara Paranagama, PhD, Smitha Sivaraman, PhD, Pavel Atanasov, Becky Hanna, Jackson Tang, Shreekant V. Parasuraman, BPharm, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1636.
https://doi.org/10.1182/blood.V130.Suppl_1.1636.1636
Published: 2017
Journal Articles

Combination of Motexafin Gadolinium (MGd) with 90 Y Ibritumomab Tiuxetan (Zevalin®; 90 Yttrium-Zevalin) Radioimmunotherapy (RIT) Produces High Complete Remission Rates in Relapsed Rituximab-Refractory Follicular Non- Hodgkin’s Lymphoma (NHL).

Andrew M. Evens, DO, MS, David Patton, BS, Stewart Spies, MD, Smitha Sivaraman, PhD, M.Wayne Saville, MD, See Phan, MD, Richard Miller, MD, Leo I. Gordon, MD
Journal: Blood
Blood (2005) 106 (11): 2450.
https://doi.org/10.1182/blood.V106.11.2450.2450
Published: 2005